Synlogic (Nasdaq: SYBX) shares are rallying premarket after the company reported positive data from clinical studies evaluating SYNB1618 and SYNB1934, investigational Synthetic Biotic medicines for the treatment of phenylketonuria (PKU).
In an interim analysis, the clinical-stage company said SYNB1618 demonstrated “clinically meaningful reductions of phenylalanine at several dose levels, across multiple time points.”
Meanwhile, SYNB1934, a strain evolved from SYNB1618, displayed two-fold higher activity than SYNB1618 in a head-to-head Phase 1 study in healthy volunteers.
Ready to put what you’ve learned into practice?
Try IG’s platform with £10,000 in virtual funds and practise trading
without putting your own money at risk.
Try IG with a demo account →
Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 69% of retail investor accounts lose money when trading spread bets and CFDs with this provider.
Learn the markets with IG Academy
Build your knowledge with IG Academy educational content, then use a
demo account to practise what you’ve learned on the IG platform.
Explore IG →
Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 69% of retail investor accounts lose money when trading spread bets and CFDs with this provider.
See how trading works before risking real money
IG’s demo gives you access to thousands of markets and £10,000 in
virtual funds, so you can explore the platform and test your ideas first.
Open an IG demo →
Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 69% of retail investor accounts lose money when trading spread bets and CFDs with this provider.
Turn trading theory into practical experience
Learn with IG Academy, explore charts and market tools, and practise
strategies in a simulated trading environment before going live.
Start practising with IG →
Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 69% of retail investor accounts lose money when trading spread bets and CFDs with this provider.
Ready to take your learning further?
IG combines market education, analysis and an established trading platform,
giving you the tools to keep learning as you develop your trading skills.
Discover IG →
Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 69% of retail investor accounts lose money when trading spread bets and CFDs with this provider.
The company now intends to incorporate SYNB1934 into part of the Phase 2 SynPheny-1 trial, with final results expected in H1 2022.
“Based on the favorable clinical data from the SYNB1618 and SYNB1934 programs available to date, the company intends to initiate planning for a pivotal Phase 3 study for the most promising strain,” Synlogic said in a statement.
Aoife Brennan, Synlogic’s President and CEO, said: “The PKU program demonstrated clear proof of concept in this analysis, with SYNB1618 achieving a clinically meaningful reduction of phenylalanine in patients across multiple endpoints and time points.
“Additionally, our second PKU candidate SYNB1934 provides greater potency, which will allow us to optimize the clinical profile to address the profound needs of patients with PKU.”
Synlogic’s share price is trading at $3.87 premarket, up 17.63% from Friday’s close.
Should You Invest in Synlogic Shares?
One of the most frequently asked questions we receive is, “what stocks are best to buy right now?” It’s a wide-ranging question, but one that we have answered… Our AskTraders stock analysts regularly review the market and compile a list of which companies you should be adding to your portfolio, including short and longer-term positions. Here are the best stocks to buy right now
